ALK阳性NSCLC-话题@MedSci

#ALK阳性NSCLC#

14篇内容 | 727人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1935437, encodeId=e97b193543e80, content=<a href='/topic/show?id=afcb2324ea' target=_blank style='color:#2F92EE;'>#ALK阳性NSCLC#</a>, objectTitle=Front Oncol：贝叶斯网状Meta分析比较ALK阳性NSCLC患者一线治疗方案的疗效和安全性, objectType=article, longId=220334, objectId=0e9e2203349a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e9e2203349a, replyNumber=0, likeNumber=38, createdTime=2022-02-16, rootId=0, userName=ms5822920152752585, userId=6bf82500013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e9e2203349a, moduleTitle=Front Oncol：贝叶斯网状Meta分析比较ALK阳性NSCLC患者一线治疗方案的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e9e2203349a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935438, encodeId=976e1935438a9, content=<a href='/topic/show?id=afcb2324ea' target=_blank style='color:#2F92EE;'>#ALK阳性NSCLC#</a>, objectTitle=Thorac Cancer：克唑替尼-阿来替尼续贯方案治疗中国晚期ALK阳性NSCLC患者的疗效, objectType=article, longId=221572, objectId=bfd12215e24f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfd12215e24f, replyNumber=0, likeNumber=42, createdTime=2022-07-25, rootId=0, userName=ms5822920152752585, userId=6bf82500013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfd12215e24f, moduleTitle=Thorac Cancer：克唑替尼-阿来替尼续贯方案治疗中国晚期ALK阳性NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bfd12215e24f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935436, encodeId=bb13193543663, content=<a href='/topic/show?id=afcb2324ea' target=_blank style='color:#2F92EE;'>#ALK阳性NSCLC#</a>, objectTitle=J Thorac Oncol：CNS渗透性TKI单药vs TKI+放疗治疗EGFR/ALK阳性NSCLC脑转移患者的疗效 , objectType=article, longId=217043, objectId=644421e04318, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=644421e04318, replyNumber=0, likeNumber=24, createdTime=2022-04-13, rootId=0, userName=ms5822920152752585, userId=6bf82500013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=644421e04318, moduleTitle=J Thorac Oncol：CNS渗透性TKI单药vs TKI+放疗治疗EGFR/ALK阳性NSCLC脑转移患者的疗效 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=644421e04318)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935435, encodeId=62421935435a1, content=<a href='/topic/show?id=afcb2324ea' target=_blank style='color:#2F92EE;'>#ALK阳性NSCLC#</a>, objectTitle=Ann Oncol：劳拉替尼用于二代TKI治疗过的ALK阳性NSCLC患者的颅内外疗效, objectType=article, longId=207814, objectId=aa0620e814a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa0620e814a1, replyNumber=0, likeNumber=46, createdTime=2022-01-16, rootId=0, userName=ms5822920152752585, userId=6bf82500013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa0620e814a1, moduleTitle=Ann Oncol：劳拉替尼用于二代TKI治疗过的ALK阳性NSCLC患者的颅内外疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa0620e814a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935434, encodeId=80531935434d8, content=<a href='/topic/show?id=afcb2324ea' target=_blank style='color:#2F92EE;'>#ALK阳性NSCLC#</a>, objectTitle=肺癌新一代靶向药劳拉替尼：显着改善ALK阳性NSCLC患者的无进展生存期, objectType=article, longId=198887, objectId=e4c319888efe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4c319888efe, replyNumber=0, likeNumber=40, createdTime=2020-11-22, rootId=0, userName=ms5822920152752585, userId=6bf82500013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4c319888efe, moduleTitle=肺癌新一代靶向药劳拉替尼：显着改善ALK阳性NSCLC患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4c319888efe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935433, encodeId=dd8c193543369, content=<a href='/topic/show?id=afcb2324ea' target=_blank style='color:#2F92EE;'>#ALK阳性NSCLC#</a>, objectTitle=ALK阳性NSCLC的治疗如何权衡PFS和OS？, objectType=article, longId=184371, objectId=c0ab1843e149, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0ab1843e149, replyNumber=0, likeNumber=33, createdTime=2020-05-08, rootId=0, userName=ms5822920152752585, userId=6bf82500013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0ab1843e149, moduleTitle=ALK阳性NSCLC的治疗如何权衡PFS和OS？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0ab1843e149)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935432, encodeId=b28b193543252, content=<a href='/topic/show?id=afcb2324ea' target=_blank style='color:#2F92EE;'>#ALK阳性NSCLC#</a>, objectTitle=ALUNBRIG（brigatinib）治疗ALK阳性NSCLC的中长期数据：两年随访展现的优势, objectType=article, longId=183563, objectId=716c183563f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=716c183563f0, replyNumber=0, likeNumber=32, createdTime=2020-08-25, rootId=0, userName=ms5822920152752585, userId=6bf82500013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=716c183563f0, moduleTitle=ALUNBRIG（brigatinib）治疗ALK阳性NSCLC的中长期数据：两年随访展现的优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=716c183563f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935431, encodeId=b9f71935431ed, content=<a href='/topic/show?id=afcb2324ea' target=_blank style='color:#2F92EE;'>#ALK阳性NSCLC#</a>, objectTitle=刘基巍教授：精准时代下ALK阳性NSCLC的治疗新选择, objectType=article, longId=176019, objectId=2bce1e60194b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2bce1e60194b, replyNumber=0, likeNumber=35, createdTime=2020-03-28, rootId=0, userName=ms5822920152752585, userId=6bf82500013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2bce1e60194b, moduleTitle=刘基巍教授：精准时代下ALK阳性NSCLC的治疗新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2bce1e60194b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935429, encodeId=1b5d193542954, content=<a href='/topic/show?id=afcb2324ea' target=_blank style='color:#2F92EE;'>#ALK阳性NSCLC#</a>, objectTitle=Ann Oncol:克唑替尼治疗过的ALK阳性NSCLC患者：艾乐替尼vs化疗, objectType=article, longId=144326, objectId=638a14432673, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=638a14432673, replyNumber=0, likeNumber=38, createdTime=2018-10-22, rootId=0, userName=ms5822920152752585, userId=6bf82500013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=638a14432673, moduleTitle=Ann Oncol:克唑替尼治疗过的ALK阳性NSCLC患者：艾乐替尼vs化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=638a14432673)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935430, encodeId=d655193543092, content=<a href='/topic/show?id=afcb2324ea' target=_blank style='color:#2F92EE;'>#ALK阳性NSCLC#</a>, objectTitle=Takeda的Alunbrig在ALK阳性NSCLC的PFS击败了辉瑞公司的Xalkori, objectType=article, longId=145287, objectId=5cfb14528e84, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cfb14528e84, replyNumber=0, likeNumber=35, createdTime=2019-05-24, rootId=0, userName=ms5822920152752585, userId=6bf82500013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cfb14528e84, moduleTitle=Takeda的Alunbrig在ALK阳性NSCLC的PFS击败了辉瑞公司的Xalkori, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cfb14528e84)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935428, encodeId=138419354289b, content=<a href='/topic/show?id=afcb2324ea' target=_blank style='color:#2F92EE;'>#ALK阳性NSCLC#</a>, objectTitle=JCO：Brigatinib二线治疗ALK阳性NSCLC有力量, objectType=article, longId=98708, objectId=105298e082a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=105298e082a, replyNumber=0, likeNumber=37, createdTime=2018-04-15, rootId=0, userName=ms5822920152752585, userId=6bf82500013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=105298e082a, moduleTitle=JCO：Brigatinib二线治疗ALK阳性NSCLC有力量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=105298e082a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935427, encodeId=d9b4193542e9f, content=<a href='/topic/show?id=afcb2324ea' target=_blank style='color:#2F92EE;'>#ALK阳性NSCLC#</a>, objectTitle=ALK阳性NSCLC治疗药物Aalectinib被FDA授予突破性药物资格, objectType=article, longId=79315, objectId=590ee9315c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=590ee9315c5, replyNumber=0, likeNumber=39, createdTime=2017-09-18, rootId=0, userName=ms5822920152752585, userId=6bf82500013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=590ee9315c5, moduleTitle=ALK阳性NSCLC治疗药物Aalectinib被FDA授予突破性药物资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=590ee9315c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935426, encodeId=18d91935426a1, content=<a href='/topic/show?id=afcb2324ea' target=_blank style='color:#2F92EE;'>#ALK阳性NSCLC#</a>, objectTitle=CSMO 2014：刘晓晴谈论ALK阳性NSCLC诊治进展及全程管理, objectType=article, longId=37519, objectId=234f3e51952, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=234f3e51952, replyNumber=0, likeNumber=46, createdTime=2014-09-19, rootId=0, userName=ms5822920152752585, userId=6bf82500013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=234f3e51952, moduleTitle=CSMO 2014：刘晓晴谈论ALK阳性NSCLC诊治进展及全程管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=234f3e51952)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935425, encodeId=697119354250a, content=<a href='/topic/show?id=afcb2324ea' target=_blank style='color:#2F92EE;'>#ALK阳性NSCLC#</a>, objectTitle=ASCO 2014：口服ceritinib治疗ALK阳性NSCLC疗效可观, objectType=article, longId=35662, objectId=312b35662d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=312b35662d6, replyNumber=0, likeNumber=35, createdTime=2015-03-01, rootId=0, userName=ms5822920152752585, userId=6bf82500013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=312b35662d6, moduleTitle=ASCO 2014：口服ceritinib治疗ALK阳性NSCLC疗效可观, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=312b35662d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ALK阳性NSCLC

2020-05-29

ms5822920152752585 (审核中...)

前往app查看评论内容

#ALK阳性NSCLC#

Front Oncol：贝叶斯网状Meta分析比较ALK阳性NSCLC患者一线治疗方案的疗效和安全性

2022-02-16

ms5822920152752585 (审核中...)

前往app查看评论内容

#ALK阳性NSCLC#

Thorac Cancer：克唑替尼-阿来替尼续贯方案治疗中国晚期ALK阳性NSCLC患者的疗效

2022-07-25

ms5822920152752585 (审核中...)

前往app查看评论内容

#ALK阳性NSCLC#

J Thorac Oncol：CNS渗透性TKI单药vs TKI+放疗治疗EGFR/ALK阳性NSCLC脑转移患者的疗效

2022-04-13

ms5822920152752585 (审核中...)

前往app查看评论内容

#ALK阳性NSCLC#

Ann Oncol：劳拉替尼用于二代TKI治疗过的ALK阳性NSCLC患者的颅内外疗效

2022-01-16

ms5822920152752585 (审核中...)

前往app查看评论内容

#ALK阳性NSCLC#

肺癌新一代靶向药劳拉替尼：显着改善ALK阳性NSCLC患者的无进展生存期

2020-11-22

ms5822920152752585 (审核中...)

前往app查看评论内容

#ALK阳性NSCLC#

ALK阳性NSCLC的治疗如何权衡PFS和OS？

2020-05-08

ms5822920152752585 (审核中...)

前往app查看评论内容

#ALK阳性NSCLC#

ALUNBRIG（brigatinib）治疗ALK阳性NSCLC的中长期数据：两年随访展现的优势

2020-08-25

ms5822920152752585 (审核中...)

前往app查看评论内容

#ALK阳性NSCLC#

刘基巍教授：精准时代下ALK阳性NSCLC的治疗新选择

2020-03-28

ms5822920152752585 (审核中...)

前往app查看评论内容

#ALK阳性NSCLC#

Ann Oncol:克唑替尼治疗过的ALK阳性NSCLC患者：艾乐替尼vs化疗

2018-10-22

ms5822920152752585 (审核中...)

前往app查看评论内容

#ALK阳性NSCLC#

Takeda的Alunbrig在ALK阳性NSCLC的PFS击败了辉瑞公司的Xalkori

2019-05-24

ms5822920152752585 (审核中...)

前往app查看评论内容

#ALK阳性NSCLC#

JCO：Brigatinib二线治疗ALK阳性NSCLC有力量

2018-04-15

ms5822920152752585 (审核中...)

前往app查看评论内容

#ALK阳性NSCLC#

ALK阳性NSCLC治疗药物Aalectinib被FDA授予突破性药物资格

2017-09-18

ms5822920152752585 (审核中...)

前往app查看评论内容

#ALK阳性NSCLC#

CSMO 2014：刘晓晴谈论ALK阳性NSCLC诊治进展及全程管理

2014-09-19

ms5822920152752585 (审核中...)

前往app查看评论内容

#ALK阳性NSCLC#

ASCO 2014：口服ceritinib治疗ALK阳性NSCLC疗效可观

2015-03-01

科室
- - 订阅+
  - 更多科室
工具
服务